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INVESTIGATIVE REPORT
A Left/Right Comparison of Twice-Daily Calcipotriol Ointment and
Calcitriol Ointment in Patients with Psoriasis: The Effect on
Keratinocyte Subpopulations
Mannon E.J. FRANSSEN, Gys J. DE JONGH, Piet E.J. VAN ERP and Peter C.M. VAN DE KERKHOF
Department of Dermatology, University Medical Centre Nijmegen, The Netherlands
Vitamin D3 analogues are a first-line treatment of
chronic plaque psoriasis, but so far, comparative clinical
studies on calcipotriol and calcitriol ointment are sparse,
and in particular no comparative studies are available on
cell biological effects of these compounds in vivo. Using
flow cytometric assessment, we investigated whether these
compounds had different effects on the composition and
DNA synthesis of epidermal cell populations responsible
for the psoriatic phenotype. For 8 weeks, 20 patients with
psoriasis vulgaris were treated twice daily with calcipo-
triol and calcitriol ointment in a left/right comparative
study. Before and after treatment, clinical assessment of
target lesions was performed, together with flow cyto-
metric analysis of epidermal subpopulations with respect
to keratin (K) 10, K6, vimentin and DNA distribution.
Treatment with each compound resulted in a substantial
clinical improvement, a reduction of the K10 –K6 –
population and an increase of the K10zK6 – population.
A correlation was found between the clinical response of
calcipotriol and the K10zK6 – population, and the
clinical response of calcitriol and the K10zK6 –
population, as well as the percentage of cells in the S,
G2 and M phase of the cell cycle within the K10 –K6 –
population, suggesting that the analogues have a different
preference for affecting the K10zK6 – pool (committed
differentiated cells) or affecting the K10 –K6 – pool
(basal cells). Key words: calcitriol; calcipotriol; psoriasis;
keratinization; proliferation; flow cytometry.
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For several years, vitamin D3 derivatives have been
used in the topical treatment of psoriasis. These
derivatives are thought to inhibit proliferation and
promote differentiation of keratinocytes of lesional
psoriatic skin. As disturbed keratinization and
increased proliferation, together with inflammation,
are key marks of psoriasis, a number of analogues were
investigated for their anti-psoriatic potential.
Calcipotriol (Daivonex1, 50 mg/g ointment, Leo
Pharmaceutical Products, Denmark) has been investi-
gated intensively during the last decade, and has proven
to be a valuable tool in the management of chronic
plaque psoriasis. A review by Ashcroft et al. (1), based on
a large number of randomized controlled trials, showed
that calcipotriol was at least as effective as potent
topical corticosteroids, 1a,-25-dihydroxycholecalciferol
(calcitriol), short-contact dithranol, tacalcitol and coal
tar. Recently, Scott et al. (2) presented an overview of
studies on the use of calcipotriol ointment in the
management of psoriasis. They reconfirmed the super-
ior efficacy of a twice-daily calcipotriol ointment
regimen to the treatments as mentioned above, and
concluded that calcipotriol ointment is valuable as a
first- or second-line therapy option for the management
of mild to moderate psoriasis.
In the last decade, calcitriol ointment (Silkis1, 3 mg/g
ointment, Galderma Laboratories, France) has been
added to the armamentarium available for the topical
treatment of psoriasis vulgaris. A few clinical studies
have been performed to establish the efficacy of
calcitriol ointment as an anti-psoriatic drug. A review
by Kowalzick (3) concluded that calcitriol applied twice
daily was as effective as short-contact dithranol treat-
ment (4). Furthermore, combining calcitriol with other
anti-psoriatic therapies such as ultraviolet B photo-
therapy or topical corticosteroids was as effective as
each therapy alone and thereby proved to have a
radiation- and corticosteroid-sparing effect (3, 5, 6). To
date, however, conclusive comparative clinical studies
between calcipotriol and calcitriol are not available.
Active vitamin D3 inhibits cell proliferation, induces
cell differentiation and modulates inflammation. Treat-
ment with calcipotriol ointment applied twice daily for
8 weeks has been reported to normalize nearly com-
pletely the morphological appearance of the psoriatic
lesion, except for persistence of capillary enlargement
(2). Findings from our group included a significant
reduction of the number of neutrophils, a reduction of
epidermal cell recruitment and expression of keratin
(K) 16, as a marker of abnormal keratinization (7 – 9).
Immunohistochemical data of a calcitriol ointment
regimen, showed a significant decrease in the number
of Ki-67-positive cells, and a significant increase in
filaggrin staining after 4 weeks of twice-daily treatment,
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together with modulation of the dermal infiltrate with a
reduction of neutrophils and T cells (10). These data
suggested that a reduction of epidermal proliferation,
normalization of keratinization and modulation of
dermal inflammatory cells are important in vivo effects
of calcipotriol and calcitriol.
As the receptor binding of calcitriol and calcipotriol
are comparable, the biological effects of both vitamin
D3 analogues are likely to be similar. However, the
pharmacokinetics of these compounds are markedly
different. Vitamin D serum protein binding of calcipo-
triol is less and the inactivation of calcipotriol is much
faster compared with calcitriol (11, 12). The concentra-
tions of calcipotriol (50 mg/g) and calcitriol ointment
(3 mg/g) are also highly different. Therefore a compara-
tive analysis regarding the cell biological action
spectrum is indicated.
The aim of the present study was to compare a
regimen of calcipotriol and calcitriol ointment applied
twice daily in patients with chronic plaque psoriasis to
elucidate the behaviour of the suprabasal and basal
compartment, and to establish the biological effect of
each therapy on different epidermal cell populations
responsible for the psoriatic phenotype in a within-
subject comparative study. The relationship between
these effects and clinical responses was investigated.
MATERIALS AND METHODS
Subjects and study design
The present study was performed as an open left/right
comparative study between calcipotriol ointment and calci-
triol ointment in patients with psoriasis vulgaris. After giving
informed consent, 20 patients from our outpatient department
(12 men and 8 women, mean age 54 years, range 29 – 71) with
psoriasis vulgaris participated. Patients were diagnosed with
stable and mild to moderate chronic plaque psoriasis. Patients
had symmetrical psoriatic lesions on the trunk and/or on
extremities. Within at least one body region the score for
extent, as part of the Psoriasis Area and Severity Index
(PASI) score was at least 2. Patients who were pregnant,
lactating or expected to become pregnant were excluded.
Patients must not have received any systemic anti-psoriatic
treatment or (chemo-) phototherapy during the 6 weeks prior
to study enrolment. All topical treatments except emollients
were discontinued for 2 weeks prior to enrolment. Patients
with a known or suspected abnormality of calcium metabo-
lism or hypercalcaemia were excluded. Exposure to sun, UVB
or UVA light was not allowed during the entire study period.
Patients were instructed to treat all psoriatic lesions twice
daily with calcitriol ointment on the left side, and calcipotriol
ointment on the right side of the body. Psoriatic lesions in the
flexures or on the face were included. In case of scalp
psoriasis, patients were allowed to use a moderate cortico-
steroid formulation three times a week on the scalp. Patients
were instructed to wash their hands between the application
of each ointment and after the applications.
Efficacy of both treatments was evaluated by clinical
scoring before treatment and after 8 weeks of treatment. The
PASI was used as an overall assessment (13). The target
lesions were at least 15 cm2 and located symmetrically on the
trunk or extremities. Using a scale ranging from 0 (no) to 8
(severe), the degree of erythema, induration and desquama-
tion was estimated for each target lesion, resulting in a sum of
scores. At each visit, the target lesions were outlined using
transparent paper, and the area of each target lesion was
calculated. Using the same method, a global sum score and
global area was calculated for each side of the body.
Biopsy procedure
Before and after 8 weeks of treatment, 3-mm punch biopsies
(Stieffel, Offenbach am Main, Germany) were taken from the
target lesions on the trunk and extremities. Biopsies were
obtained after local anaesthesia with xylocaine/adrenaline
1:100 000 (Astra Pharmaceutica BV, Zoetermeer, The
Netherlands) and kept in phosphate-buffered saline (PBS,
NPBI, Emmer-Compascuum, The Netherlands) at 4‡C.
Cell isolation procedure
Epidermal single cell suspensions were prepared as described
previously (14). In brief, biopsies were placed in an overnight
solution of 2.5 ml PBS with Ca2z/Mg2z, containing 0.5 mg/ml
thermolysin (Protease type X, Sigma, St Louis, MO, USA)
and kept at 4‡C. After incubation, the epidermis and dermis
were gently separated using two fine forceps, and the
epidermis was incubated at 37‡C in 2.5 ml PBS, containing
0.025 mg/ml trypsin (Sigma) and 0.3 mg/ml dithioerythritol
(DTE, Sigma). After 30 min, the trypsinization was stopped
by adding 10% newborn bovine serum (NBS), and the cell
suspension was gently mixed on a vortex, allowing keratino-
cytes to detach from the remaining stratum corneum. After
centrifuging and decanting the supernatant, the remaining cell
pellet was fixed in 70% ethanol and kept at 220‡C until
further processing.
Staining procedure
The staining procedure and the flow cytometric assessment
have been described previously (15). We adjusted the protocol
by adding a marker for inflammation (16). In brief: a four-
parameter protocol allowed simultaneous assessment of epidermal
proliferation, hyperproliferation-associated differentiation,
keratinization and inflammation. An IgG1-isotype mouse
monoclonal antibody directed against cytokeratin 10,
RKSE60 (clone RKSE60, Sanbio, Uden, The Netherlands),
was used to assess epidermal differentiation. To assess
hyperproliferation-associated differentiation, LHK6B (NCL-
CK6, Novocastra Laboratories, New Castle upon Tyne, UK),
an IgG2a-isotype mouse monoclonal antibody directed against
cytokeratin 6 was used. Mesenchymal cells were measured
by using V9 (clone V9, Sanbio, Uden, The Netherlands), an
IgG1-isotype mouse monoclonal antibody directed against
vimentin.
A sample of approximately 26105 cells from each cell
suspension was washed, and incubated with a solution
containing RKSE60, LHK6B and V9 at a dilution of 1:20
in the dark for 30 min at room temperature. After a washing
step, a solution containing goat anti-mouse (GAM) IgG1
conjugated with phycoerythrin (GAM-PE, Southern Biotech-
nology Associates, Birmingham, AL, USA) at a dilution of
1:100, and goat anti-mouse IgG2a conjugated with fluores-
cein isothiocyanate (GAM-FITC, Southern Biotechnology
Associates) at a dilution of 1:50 was added and incubated
on ice for 15 min. As a DNA stain 4’,6-diamidino-2-
phenylindole, dihydrochloride (DAPI, Molecular Probes,
Eugene, OR, USA) was diluted 1000 times in PBS containing
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0.1% Triton X-100 and added to each sample, with a final
concentration of 1 mM.
Flow cytometric analysis
After the staining procedure, all samples were measured and
analysed with an EPICS Elite flow cytometer (Coulter, Luton,
UK) with a dual laser system. An air-cooled argon ion laser
(20 mW, 488 nm) excited PE and FITC, while a water-cooled
argon ion laser tuned at 365 nm (80 mW) excited DAPI. By
separating the two laser beams spatially, the fluorescent
signals were detected 40 ms apart. Finally, bandpass filters at
450 nm (DAPI), 525 nm (PE) and 575 nm (FITC) conducted
the signals to photomultipliers and a gated amplifier.
The area/peak ratio of the DAPI signal (DNA) combined
with scatter parameters was used to exclude debris, and to
discriminate between doublets and real tetraploid cells, as
described previously (17). Using WinList software (WinList
4.0, Verity Software House, Topham, ME, USA), regions
were set for K10-positive cells, K6-positive cells, K6/K10 co-
expressing cells and vimentin-positive cells. A count stop was
set at 10 000 single cells. Using ModFit software (ModFit LT
2.0, Verity Software House), the proportion of cells in
different phases of the cell cycle was calculated, as described
previously (18).
Statistical analysis
For estimating the changes in the clinical scores (PASI, sum
of scores, area) during both treatments, we performed a
repeated two-way analysis of variance (ANOVA). The
changes in the epidermal subpopulations during treatment
with calcipotriol and calcitriol ointment were also analysed by
a repeated two-way ANOVA. To establish the relationship
between changes in clinical scores and changes in the
epidermal subpopulations, a stepwise multiple regression
analysis was performed and a correlation coefficient was
determined.
RESULTS
Clinical response
The PASI score before treatment was 7.89¡0.58 (n~20)
and the percentage of body surface involved was
3.09¡0.36 for the calcipotriol-treated side and 3.23¡
0.37 for the calcitriol-treated side. These values indicate
that patients suffered from mild to moderate disease.
Finally, after 8 weeks of treatment, the PASI score showed
an overall decrease of 54% from 7.89¡0.58 to 3.61¡0.42
(Pv0.001).
The sum of scores for the target lesion showed a
remarkable improvement during 8 weeks of treatment
for both therapies, as depicted in Fig. 1a. Treatment
with calcipotriol resulted in a decrease of 74% from
12.6¡0.93 to 3.25¡0.51 after 8 weeks (Pv0.001).
Treatment with calcitriol gave an improvement of the
sum of scores of 65% from 12.85¡0.92 to 4.55¡0.52 in
8 weeks (Pv0.001).
Treatment with both vitamin D analogues resulted in
a significant decrease in the area of the target lesion
after 8 weeks, as shown in Fig. 1b. Treatment with
calcipotriol resulted in a decrease of 43% to 21.85¡3.63
after 8 weeks of treatment (Pv0.05). During calcitriol
treatment, the affected area improved by 48% after
8 weeks to 19.85¡2.87 (Pv0.05). The global sum of
scores improved significantly during 8 weeks of
treatment for both calcipotriol and calcitriol ointment,
Fig. 1. Mean sum of scores¡SEM (a) and mean area (cm2)¡SEM (b) for the target lesions before and after treatment with calcitriol
(black bars) and calcipotriol (striped bars). Global sum of scores¡SEM for all treated lesions (c) and global area (%)¡SEM for all treated
lesions (d) before and after treatment with calcitriol (black bars) and calcipotriol (striped bars).
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which is illustrated in Fig. 1c. The global area score
showed a significant decrease after 8 weeks of vitamin
D treatment (Fig. 1d).
Changes in epidermal subpopulations
No significant changes in the percentage of vimentin-
positive cells before and after each treatment were
detected. Regarding the subpopulations of K10- and/or
K6-expressing cells (depicted in Fig. 2a and b), the
subpopulation of K10zK6 – cells showed a significant
increase from 23.05%¡4.13 to 39.25%¡4.50 during
calcipotriol treatment (Pv0.05). During calcitriol treat-
ment, the number of K10zK6 – cells increased from
23.52%¡4.07 to 32.56%¡4.34; however, this increase
was not significant. No significant differences were
found between both therapies. The K10 – K6 – expres-
sing cells showed a significant decrease from 48.92%¡
2.85 to 40.10%¡2.62 during calcipotriol treatment
(Pv0.05). During calcitriol treatment, the number
of K10 – K6 – cells decreased from 50.80%¡2.2 to
43.98%¡2.58, but again this was not significant. No
significant differences with respect to the changes in the
K10 – K6 – population were found between both
therapies. The subpopulation of K10zK6z cells and
K10 – K6z cells showed no significant changes during
both calcipotriol and calcitriol treatment.
With regard to the overall K10 or K6 expression,
overall K10 expression showed a significant increase
during calcipotriol treatment from 42.52%¡3.73 to
54.82%¡3.11 (Pv0.05). Treatment with calcitriol resulted
in an increase of K10 expression from 41.10%¡3.07 to
49.32%¡3.34, but this was not significant. No signi-
ficant differences with respect to these changes were
found between the two therapies. The overall K6
expression did not show significant changes during
either calcipotriol or calcitriol treatment. Assessment of
cells in the S, G2 and M phase of the cell cycle within
the K10 – K6 – compartment showed no significant
changes during either treatment.
Comparing clinical results with changes in epidermal
subpopulations
A stepwise multiple regression analysis was performed,
correlating the changes in clinical scores to changes in
the different epidermal subpopulations. As clinical scores,
we assessed the changes in the sum score and the area of
the target lesion, together with changes in the sum score
and the area of all treated lesions during both calcipotriol
treatment and calcitriol treatment. Using flow cytometric
analysis, changes in epidermal subpopulations with
respect to K10 – or K6 – expressing cells, K10/K6 co-
expressing cells, vimentin-positive cells, and the percentage
of cells in SG2M phase of the cell cycle in the population of
K10 – K6 – cells were assessed. During anti-psoriatic
treatment, changes in the composition of epidermal
populations resulted in the improvement of the clinical
scores of a psoriatic lesion. Therefore, a stepwise multiple
regression analysis was performed, linking the effect of
each vitamin D3 treatment on a clinical score to a specific
epidermal subpopulation which covariates with the
changes in the clinical score. An example is shown in
Fig. 3; it illustrates the effect of calcipotriol treatment on
the global sum of scores, which is predicted from the
changes in the K10zK6 – subpopulation. In Table I, the
results of all clinical scores are depicted, together with
the correlation coefficients (R) for each corresponding
epidermal subpopulation. As can be seen, clinical
improvement during calcipotriol treatment, which
resulted in a decrease of both the sum score of the target
lesion and of all treated lesions, is highly correlated with
the changes in the K10zK6 – subpopulation. Clinical
improvement during calcitriol treatment resulting in a
decrease of the global sum score, correlated with changes
in the K10zK6 – subpopulation, and with changes in the
percentage of cells in the SG2M phase of the cell cycle in
the K10 – K6 – compartment. The correlating epidermal
subpopulations are depicted, which correlate with the
decrease in the global sum score during calcitriol
treatment. As can be seen, the b coefficient of the
percentage of cells in the SG2M phase of the cell cycle is
five times higher than the b coefficient for the K10zK6 –
subpopulation, suggesting a preferential effect of calcitriol
on this subpopulation.
DISCUSSION
In the present study, a relevant clinical improvement
was found after treatment with both calcipotriol and
Fig. 2. Mean percentage of K10zK6 – cells (¡SEM) (a) and mean percentage of K10 – K6 – cells (¡SEM) (b) before and after 8 weeks of
treatment with calcitriol (black bars) and calcipotriol (striped bars).
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calcitriol ointment twice daily. The overall PASI score,
comprising both body sides, improved by 54%, which is
in line with percentages found in other studies (4, 10,
19, 20). Both treatments resulted in a clinically relevant
improvement as judged by the investigator and
experienced by the patient.
Regarding the effect of both calcipotriol and
calcitriol ointment on the epidermal cell populations
responsible for the psoriatic phenotype, a flow cyto-
metric assessment of epidermal keratinization, prolif-
eration and inflammation showed only mild changes in
these subpopulations. We did find a significant increase
in the K10zK6 – subpopulation and a significant
decrease in the K10 – K6 – subpopulation during
calcipotriol treatment. During calcitriol treatment a
similar tendency was found, without reaching the level
of statistical significance. These data suggest a normal-
ization of keratinization, together with a decrease in the
number of basal cells. However, we could only observe
a tendency towards normalization in the number of
hyperproliferative K10 – K6z cells; again without
reaching the level of significance. Furthermore, we
did not observe a statistically significant change in the
number of cells in the S, G2 or M phase of the cell
cycle. Gerritsen et al. (10) reported a significant
decrease in the number of Ki-67-positive cells after 4
weeks of calcitriol treatment. With respect to the in vivo
effects of calcitriol, no analyses of the percentage of
cells in the S, G2 or M phase of the cell cycle using flow
cytometry have been reported. Treatment with calcipo-
triol also showed a significant decrease in the Ki-67-
positive cells, according to van der Vleuten et al. (8).
Furthermore, de Mare et al. (9) reported a significant
decrease of cells in the SG2M phase of the cell cycle
during calcipotriol treatment. However, the previous
flow cytometric analysis has been carried out by single
parameter flow cytometry, and it is highly likely that
differences in epidermal subpopulations have confused
these previous results, suggesting differences in the
percentage of cells in the SG2M phase of the cell cycle.
Taking these findings together, vitamin D3 analogues
are effective in the treatment of psoriasis, but the mode
of action has still to be elucidated. Because of the
in vitro effects of vitamin D3 and its derivatives, one
may speculate whether the hormone acts on keratino-
cytes, antigen-presenting cells, T cells or a combination
of these. However, in vivo studies as described above
indicate that the effect of vitamin D3 analogues in
psoriasis is primarily due to an effect on keratinocyte
proliferation.
Fig. 3. An example of a stepwise multiple regression test, correlating changes in clinical scores to changes in epidermal subpopulations
during treatment. The correlation of the calcipotriol effect on the global sum score of all treated lesions and the K10zK6 – population is
depicted.
Table I. Results of a stepwise multiple regression test, correlating changes in clinical scores to changes in epidermal subpopula-
tions during treatment with calcitriol and calcipotriol
Ointment Clinical score R (corr. coeff.) Corresponding epidermal subpopulation P value
Calcipotriol Sum target 0.716 K10zK6 – 0.000258
Calcipotriol Area target 0.675 K10 – K6z 0.058853
Calcipotriol Sum global 0.713 K10zK6 – 0.000287
Calcipotriol Area global Not available
Calcitriol Sum target 0.640 %SG2M K10 – K6 – 0.008417
Calcitriol Area target Not available
Calcitriol Sum global 0.709 K10zK6 – * 0.044621
Calcitriol Sum global 0.709 %SG2M K10 – K6 – ** 0.008141
Calcitriol Area global 0.543 K10zK6 – 0.011031
*b coefficient 20.404, **b coefficient 2.085. Notice a b coefficient 5 times higher for the percentage of cells in SG2M phase of the cell cycle in the
K10 – K6 – population as compared with the K10zK6 – population.
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We performed a correlation test linking the clinical
results to the flow cytometric data. As depicted in
Table I, clinical improvement during calcipotriol treat-
ment correlated with changes in the subpopulation of
K10zK6 – cells. This suggests a preferential effect of
calcipotriol on epidermal differentiation, resulting in
normalization of keratinization. During calcitriol treat-
ment, a similar correlation was found between the
clinical changes and the K10zK6 – subpopulation.
Nevertheless, a fivefold stronger correlation was found
with the number of cells in the SG2M phase of the cell
cycle within the K10 – K6 – subpopulation. This sug-
gested not only an effect of calcitriol on suprabasal
keratinocytes resulting in normalization of differentia-
tion, but even more distinctly treatment with calcitriol
seemed to have a more preferential effect on the basal
compartment in the epidermis.
Antiproliferative and keratinization-enhancing effects
of vitamin D3 analogues are mediated by activation of
the vitamin D3 receptor. In vitro studies have not
revealed any difference in this respect between calcipo-
triol and calcitriol. In the in vivo situation, however, the
differences between both treatments with respect to
pharmacokinetics could well have an impact on the skin
compartment on which each of them might have a
preferential effect. Indeed, the present study suggests
that the K10zK6 – population is more relevant to the
anti-psoriatic efficacy of calcipotriol as compared to
the effects on the K10 – population, whereas both the
K10z (suprabasal compartment comprising committed
differentiated cells) and K10 – populations (basal
compartment comprising stem cells and transit amplify-
ing cells) are relevant to the effects of calcitriol.
Further studies reconciling the keratinocyte sub-
populations (stem cells, transit amplifying cells and
committed keratinizing cells) may help to define
more precisely the in vivo mode of action of treat-
ments that interfere with epidermal proliferation and
differentiation.
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